Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research.
Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research.
